Praluent Sales to Resume as Sanofi, Regeneron Win New Infringement Trial
A federal appeals court on Thursday ordered a new trial in a high-profile patent infringement dispute over Sanofi's drug Praluent and lifted a permanent injunction barring sales of the biologic, used to fight high cholesterol.
This premium content is reserved for Delaware Law Weekly subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now